JW (Cayman) Therapeutics Past Earnings Performance
Past criteria checks 0/6
JW (Cayman) Therapeutics has been growing earnings at an average annual rate of 10.1%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been growing at an average rate of 55.7% per year.
Key information
10.1%
Earnings growth rate
54.0%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 55.7% |
| Return on equity | -42.4% |
| Net Margin | -363.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Take Care Before Jumping Onto JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Even Though It's 26% Cheaper
Nov 12
JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Screens Well But There Might Be A Catch
Sep 25A Piece Of The Puzzle Missing From JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) 34% Share Price Climb
May 10Calculating The Intrinsic Value Of JW (Cayman) Therapeutics Co. Ltd (HKG:2126)
May 03JW (Cayman) Therapeutics Co. Ltd (HKG:2126): When Will It Breakeven?
Feb 03Revenue & Expenses Breakdown
How JW (Cayman) Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 173 | -628 | 250 | 348 |
| 31 Mar 24 | 173 | -698 | 252 | 381 |
| 31 Dec 23 | 174 | -768 | 253 | 414 |
| 30 Sep 23 | 171 | -783 | 294 | 421 |
| 30 Jun 23 | 167 | -797 | 334 | 428 |
| 31 Mar 23 | 157 | -822 | 352 | 418 |
| 31 Dec 22 | 146 | -846 | 371 | 408 |
| 30 Sep 22 | 121 | -849 | 383 | 416 |
| 30 Jun 22 | 97 | -851 | 396 | 425 |
| 31 Mar 22 | 64 | -777 | 384 | 420 |
| 31 Dec 21 | 31 | -702 | 372 | 414 |
| 30 Sep 21 | 15 | -998 | 344 | 371 |
| 30 Jun 21 | -1 | -1,294 | 315 | 328 |
| 31 Mar 21 | 0 | -1,479 | 280 | 277 |
| 31 Dec 20 | 0 | -1,664 | 245 | 225 |
| 30 Sep 20 | 3 | -1,295 | 186 | 195 |
| 30 Jun 20 | 6 | -925 | 128 | 164 |
| 31 Mar 20 | 6 | -779 | 101 | 150 |
| 31 Dec 19 | 5 | -633 | 73 | 136 |
| 31 Dec 18 | 0 | -273 | 41 | 76 |
Quality Earnings: 2126 is currently unprofitable.
Growing Profit Margin: 2126 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2126 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.1% per year.
Accelerating Growth: Unable to compare 2126's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2126 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 2126 has a negative Return on Equity (-42.37%), as it is currently unprofitable.